×
Join our live online event
How top hedge funds use news to make money
form the stock market & how ordinary people are
copying their strategies
Register now!
form the stock market & how ordinary people are
copying their strategies
No thanks
SGMO – sangamo therapeutics, inc. (US:NASDAQ)
DELAYED
$
| Volume Shares | |
| 1 Day Range | |
| Volume Ratio | |
| 52 Week High | |
| 52 Week Low |
| VWAP | |
| Today’s Volatility | |
| 20 Days Volatility | |
| Open | |
| Prior Close |
1D
5D
1M
3M
YTD
1Y
3Y
1 Day
SGMO
SPY
QQQ
Swipe to see more
Main News & Impact Reports
Date
Time
Symbol
Headline
Impact
2/3
06:05 pm
sgmo
Sangamo Therapeutics Presents Detailed Data from Registrational STAAR Study in Fabry Disease at WORLDSymposium™ 2026 [Yahoo! Finance]
Medium
Report
Sangamo Therapeutics Presents Detailed Data from Registrational STAAR Study in Fabry Disease at WORLDSymposium™ 2026 [Yahoo! Finance]
2/3
04:05 pm
sgmo
Sangamo Therapeutics Presents Detailed Data from Registrational STAAR Study in Fabry Disease at WORLDSymposium™ 2026
Medium
Report
Sangamo Therapeutics Presents Detailed Data from Registrational STAAR Study in Fabry Disease at WORLDSymposium™ 2026
2/3
09:10 am
sgmo
Sangamo Therapeutics Announces Pricing of $25.0 Million Underwritten Offering
High
Report
Sangamo Therapeutics Announces Pricing of $25.0 Million Underwritten Offering
1/23
07:09 pm
sgmo
How The Pulled Price Target Is Reshaping The Story For Sangamo Therapeutics (SGMO) [Yahoo! Finance]
Low
Report
How The Pulled Price Target Is Reshaping The Story For Sangamo Therapeutics (SGMO) [Yahoo! Finance]
1/12
04:40 am
sgmo
Sangamo Therapeutics (SGMO) Shares Stabilize Amid Recent Key Pipeline Update [Yahoo! Finance]
Low
Report
Sangamo Therapeutics (SGMO) Shares Stabilize Amid Recent Key Pipeline Update [Yahoo! Finance]
1/6
08:17 am
sgmo
Atsena Therapeutics Appoints McDavid Stilwell as Chief Financial Officer [Yahoo! Finance]
Medium
Report
Atsena Therapeutics Appoints McDavid Stilwell as Chief Financial Officer [Yahoo! Finance]
12/18
09:05 am
sgmo
Sangamo Therapeutics Initiates Rolling Submission of BLA to U.S. FDA for ST-920 in Fabry Disease [Yahoo! Finance]
Medium
Report
Sangamo Therapeutics Initiates Rolling Submission of BLA to U.S. FDA for ST-920 in Fabry Disease [Yahoo! Finance]
Date
Time
Symbol
Company Name
Action
%Chg
11/6/2025
08:01 am
SGMO
sangamo therapeutics, inc.
MISS
Report
4.6%
sangamo therapeutics, inc.
8/7/2025
04:01 pm
SGMO
sangamo therapeutics, inc.
MISS
Report
-5.3%
sangamo therapeutics, inc.
5/12/2025
04:01 pm
SGMO
sangamo therapeutics, inc.
MISS
Report
-38.4%
sangamo therapeutics, inc.
3/17/2025
04:01 pm
SGMO
sangamo therapeutics, inc.
MISS
Report
-17.8%
sangamo therapeutics, inc.
Date
Time
Action
From
To
Firm
Impact
%Chg
Date
Time
Symbol
Headline
Impact
2/4
08:36 am
sgmo
Form 8-K SANGAMO THERAPEUTICS, For: Feb 03
High
Report
Form 8-K SANGAMO THERAPEUTICS, For: Feb 03
2/4
08:31 am
sgmo
Form 424B5 SANGAMO THERAPEUTICS,
High
Report
Form 424B5 SANGAMO THERAPEUTICS,
2/3
04:07 pm
sgmo
Form 8-K SANGAMO THERAPEUTICS, For: Feb 03
Medium
Report
Form 8-K SANGAMO THERAPEUTICS, For: Feb 03
2/3
09:07 am
sgmo
Form FWP SANGAMO THERAPEUTICS, Filed by: SANGAMO THERAPEUTICS, INC
High
Report
Form FWP SANGAMO THERAPEUTICS, Filed by: SANGAMO THERAPEUTICS, INC
2/3
08:56 am
sgmo
Form 8-K SANGAMO THERAPEUTICS, For: Feb 02
High
Report
Form 8-K SANGAMO THERAPEUTICS, For: Feb 02
1/26
04:15 pm
sgmo
Form 4 SANGAMO THERAPEUTICS, For: Jan 22 Filed by: Jain Nikunj
Low
Report
Form 4 SANGAMO THERAPEUTICS, For: Jan 22 Filed by: Jain Nikunj
1/26
04:14 pm
sgmo
Form 4 SANGAMO THERAPEUTICS, For: Jan 22 Filed by: Duraibabu Prathyusha
Low
Report
Form 4 SANGAMO THERAPEUTICS, For: Jan 22 Filed by: Duraibabu Prathyusha
1/26
04:12 pm
sgmo
Form 4 SANGAMO THERAPEUTICS, For: Jan 22 Filed by: Willoughby Scott B.
Low
Report
Form 4 SANGAMO THERAPEUTICS, For: Jan 22 Filed by: Willoughby Scott B.
Stock Stats
| News Stats | |
|---|---|
| All News | |
| News Wires | |
| Media Monitoring | |
| SEC Edgar Filings | |
| Upgrades | |
| Downgrades | |
| Initiated | |
| Reiterated | |
| Last Earnings | |
| Last Earnings EPS | |
| Next Earnings | |
| Order Stats |
|---|
| Sub-Penny |
|
|
| Odd lot |
|
|
| Avg. bid-ask spread |
|
|
| Avg. bid-ask size |
|
|
| Shares at ask/bid |
|
|
| Off exchange |
|
|
Main News & Impact Reports
TOP News Gainers
2/27
Biogen and Sangamo Announce Global Collaboration to Develop Gene Regulation Therapies for Alzheimer’s, Parkinson’s, Neuromuscular, and Other Neurological Diseases
33.3%
4/2 Form DEF 14A SANGAMO THERAPEUTICS, For: May 18 8.8%
4/17 Form 8-K SANGAMO THERAPEUTICS, For: Apr 13 8.6%
3/16 Sangamo's Partnership With Biogen Is Only One Big Pharma Partnership Based Off Of Pipeline [Seeking Alpha] 8.2%
3/18 Form 4 SANGAMO THERAPEUTICS, For: Mar 16 Filed by: DILLY STEPHEN GEORGE 7.5%
4/9 Sangamo Announces Closing of Biogen Collaboration Agreement 6.9%
12/23 Form 8-K SANGAMO THERAPEUTICS, For: Dec 17 6.4%
4/28 Form 4 SANGAMO THERAPEUTICS, For: Apr 25 Filed by: Duraibabu Prathyusha 6.0%
5/15 Sangamo Therapeutics Announces Presentations At Upcoming Scientific, Medical And Investor Conferences 5.9%
11/8 Sangamo Therapeutics Announces New Scientific Advisory Board 5.5%
4/2 Form DEF 14A SANGAMO THERAPEUTICS, For: May 18 8.8%
4/17 Form 8-K SANGAMO THERAPEUTICS, For: Apr 13 8.6%
3/16 Sangamo's Partnership With Biogen Is Only One Big Pharma Partnership Based Off Of Pipeline [Seeking Alpha] 8.2%
3/18 Form 4 SANGAMO THERAPEUTICS, For: Mar 16 Filed by: DILLY STEPHEN GEORGE 7.5%
4/9 Sangamo Announces Closing of Biogen Collaboration Agreement 6.9%
12/23 Form 8-K SANGAMO THERAPEUTICS, For: Dec 17 6.4%
4/28 Form 4 SANGAMO THERAPEUTICS, For: Apr 25 Filed by: Duraibabu Prathyusha 6.0%
5/15 Sangamo Therapeutics Announces Presentations At Upcoming Scientific, Medical And Investor Conferences 5.9%
11/8 Sangamo Therapeutics Announces New Scientific Advisory Board 5.5%
TOP News Decliners
3/14
Sangamo Therapeutics Inc (NASDAQ: SGMO) was downgraded by analysts at BidaskClub from a "sell" rating to a "strong sell" rating.
-25.2%
12/9 Sangamo Therapeutics Inc (NASDAQ: SGMO) had its "buy" rating re-affirmed by analysts at Cowen Inc. -17.4%
5/8 Q1/2019 3/31/2019 EPS -0.410 ZacksConsensus -0.270 ActVsEst (0.140) - Miss -14.8%
2/28 Q4/2019 12/31/2019 EPS 0.040 ZacksConsensus -0.310 ActVsEst 0.350 - Beat -8.4%
8/7 Sangamo Therapeutics Reports Second Quarter 2019 Financial Results -6.1%
3/2 AbbVie Is A Notable Coronavirus Responder — But Is ABBV Stock A Buy? [Investor's Business Daily] -6.0%
4/21 Mogrify and Sangamo Announce Collaboration and Exclusive License Agreement for Mogrify’s iPSC- and ESC-Derived Regulatory T Cells -5.9%
4/2 Sangamo Therapeutics Inc (NASDAQ: SGMO) was upgraded by analysts at ValuEngine from a "hold" rating to a "buy" rating. -5.3%
1/25 Sangamo Therapeutics Inc (NASDAQ: SGMO) was downgraded by analysts at BidaskClub from a "sell" rating to a "strong sell" rating. -4.9%
9/30 Sangamo Therapeutics Appoints Bettina M. Cockroft, MD, MBA, as Senior Vice President and Chief Medical Officer -4.8%
12/9 Sangamo Therapeutics Inc (NASDAQ: SGMO) had its "buy" rating re-affirmed by analysts at Cowen Inc. -17.4%
5/8 Q1/2019 3/31/2019 EPS -0.410 ZacksConsensus -0.270 ActVsEst (0.140) - Miss -14.8%
2/28 Q4/2019 12/31/2019 EPS 0.040 ZacksConsensus -0.310 ActVsEst 0.350 - Beat -8.4%
8/7 Sangamo Therapeutics Reports Second Quarter 2019 Financial Results -6.1%
3/2 AbbVie Is A Notable Coronavirus Responder — But Is ABBV Stock A Buy? [Investor's Business Daily] -6.0%
4/21 Mogrify and Sangamo Announce Collaboration and Exclusive License Agreement for Mogrify’s iPSC- and ESC-Derived Regulatory T Cells -5.9%
4/2 Sangamo Therapeutics Inc (NASDAQ: SGMO) was upgraded by analysts at ValuEngine from a "hold" rating to a "buy" rating. -5.3%
1/25 Sangamo Therapeutics Inc (NASDAQ: SGMO) was downgraded by analysts at BidaskClub from a "sell" rating to a "strong sell" rating. -4.9%
9/30 Sangamo Therapeutics Appoints Bettina M. Cockroft, MD, MBA, as Senior Vice President and Chief Medical Officer -4.8%
Don’t Miss Out On The Next BIG Stock Move
Never get left behind with our daily ‘Shakers & Movers’ newsletter. Discover the biggest gainer or loser in the stock market, and learn exactly WHY it moved. To find out which one caught Wall Street by surprise TODAY, sign up to our newsletter below: